It is a broadly described annual report of The IBN SINA Pharmaceutical Industry Limited in the year of 2013. During the financial year, company’s net profit after tax Taka. 87,176,8. The company’s total shareholders’ equity and liabilities Taka. 1,096,432,108/-. The company qualifies as a “Publicly Traded Company”. The provision of taxation was made at 27.50%. During the year the company earned foreign exchange of US $ 297,003.40 equivalent to Tk.23,045,539.00 on account of export sale but did not earn or receive any income in respect of royalty, technical know-how, professional & advisory fees, interest & dividend. The Board of Directors at its meeting no.215th held on 12.04.14 recommended to the shareholders 25% cash dividend and 10% stock dividend for the year ended 31st December 2013 which will be considered for approval by the shareholders at the 30th Annual General Meeting.
The Financial Statements of the Company have been prepared on going concern basis under historical cost convention, subject revaluation of certain fixed assets and in accordance with the Bangladesh Accounting Standards (BAS) and Bangladesh Financial Reporting Standards (BFRS).
More Annual Report of The IBN SINA Pharmaceutical Industry Limited:
- Annual Report 2010 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2011 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2012 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2013 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2014 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2017 of The IBN SINA Pharmaceutical Industry Limited
